JNJ.N
Latest Trade
131.09USDChange
-0.56(-0.43%)Volume
355,028Today's Range
-
131.7652 Week Range
-
148.97As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 131.65 |
|---|---|
Open | 131.02 |
Volume | 355,028 |
3M AVG Volume | 154.01 |
Today's High | 131.76 |
Today's Low | 130.50 |
52 Week High | 148.97 |
52 Week Low | 122.00 |
Shares Out (MIL) | 2,639.17 |
Market Cap (MIL) | 347,446.20 |
Forward P/E | 15.30 |
Dividend (Yield %) | 2.89 |
U.S. FDA Approves Supplemental New Drug Application For ERLEADA For Treatment Of Patients With Metastatic Castration-Sensitive Prostate Cancer
Janssen Submits Application To U.S. FDA Seeking First-In-Class Approval Of Tremfya (Guselkumab) For Treatment Of Adults With Active Psoriatic Arthritis
New Data From Spravato CIII Nasal Spray Phase 3 Studies Showed Rapid Reduction Of Depressive Symptoms
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Industry
Biotechnology & Drugs
Executive Leadership
Alex Gorsky
Chairman of the Board, Chief Executive Officer
Paulus A. Stoffels
Vice Chairman- Executive Committee, Chief Scientific Officer
Joaquin Boix Duato
Vice Chairman - Executive Committee
Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Peter M. Fasolo
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM) | 21.83 |
|---|---|
Price To Sales (TTM) | 4.27 |
Price To Book (MRQ) | 5.72 |
Price To Cash Flow (TTM) | 14.93 |
Total Debt To Equity (MRQ) | 48.40 |
LT Debt To Equity (MRQ) | 45.57 |
Return on Investment (TTM) | 12.98 |
Return on Equity (TTM) | 10.52 |
A drug wholesaler must submit its claims that Johnson & Johnson is illegally suppressing competition for its rheumatoid arthritis treatment Remicade to an arbitrator, a federal appeals court held on Friday.
Bayer <BAYGn.DE> said it hired Johnson & Johnson <JNJ.N> executive Marianne De Backer to manage acquisitions and licensing deals at its drugs unit, as the German drugmaker turns to outside sources to boost its development pipeline.
* Dow down 0.35%, S&P 500 down 0.28%, Nasdaq down 0.39% (Updates to mid-afternoon, changes byline)
* Indexes: Dow & S&P 500 flat, Nasdaq off 0.04% (Updates prices, comments)
An Oklahoma judge on Monday ordered Johnson & Johnson <JNJ.N> to pay $572.1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers, a sum that was substantially less than investors had expected, driving up J&J's shares.
A lawsuit by Oklahoma's attorney general accusing Johnson & Johnson of fueling the opioid epidemic is set to establish a major precedent over whether a state's public nuisance laws can be used to hold a drugmaker liable for the U.S. drug crisis.
British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.
Oklahoma's attorney general on Wednesday made his final bid to force Johnson & Johnson to pay $17 billion for its part in fueling the opioid epidemic, saying the drugmaker's "egregious" marketing caused an oversupply of addictive drugs and overdose deaths.
The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on...
Johnson & Johnson <JNJ.N> on Tuesday boosted its 2019 sales forecast amid robust demand for its cancer drugs, but warned that competition from generic and copycat drugs could impact its third-quarter results, sending shares down 1.4% in noon trading.
Johnson & Johnson reported a 41.8% rise in second-quarter profit on Tuesday, helped by its pharmaceuticals business.
Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson <JNJ.N> to a drug cartel leader as they sought to hold the drugmaker responsible for fueling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis.
Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson to a drug cartel leader as they sought to hold the drugmaker responsible for fueling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis.
Oklahoma's attorney general is expected on Monday to urge a judge to find Johnson & Johnson responsible for flooding the market with painkillers and fueling the U.S. opioid epidemic, as the first trial in nationwide litigation over the drug crisis comes to an end.
The U.S. Justice Department is pursuing a criminal probe into whether Johnson & Johnson lied about potential cancer risks of its talcum powder and has convened a grand jury in Washington, Bloomberg reported on Friday, citing people with knowledge of the matter.
California on Monday will be the first state to take Johnson & Johnson to trial over allegations that it misrepresented the risks of serious conditions women using its pelvic mesh devices could develop.
Johnson & Johnson said on Friday it plans to conduct a late-stage study of its investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.
Groundbreaking litigation can make for strange alliances.
Johnson & Johnson's greed led the drugmaker to use deceptive marketing to create an oversupply of painkillers that fueled the U.S. opioid epidemic, the state of Oklahoma alleged at the start of the first trial to result from lawsuits over the drug crisis.
Teva Pharmaceutical Industries Ltd said on Sunday it had agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that it and other drugmakers helped fuel the U.S. opioid epidemic.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.